CervoMed (CRVO) Cash from Financing Activities (2010 - 2026)

CervoMed has reported Cash from Financing Activities for 16 years, with the latest figure at $13800.0 in Q1 2026.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $13800.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (up 4412.88% YoY) and the FY2025 annual result came in at $4.6 million, down 90.11% from the prior year.
• Cash from Financing Activities eased to $13800.0 in Q1 2026 per CRVO's latest filing, from $4.6 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $11.2 million in Q3 2023 and troughed at -$93375.0 in Q4 2023.
• A 5-year average of $2.2 million and a median of $5000.0 in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities surged 224949.78% in 2023, then tumbled 100.12% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$5000.0 in 2022, then slumped by 1767.5% to -$93375.0 in 2023, then surged by 85.71% to -$13340.0 in 2024, then soared by 34497.95% to $4.6 million in 2025, then tumbled by 99.7% to $13800.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $13800.0, $4.6 million, and -$13340.0 for Q1 2026, Q2 2025, and Q3 2024 respectively.